These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 28977438

  • 1. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA, Talbot K, Bowerman M.
    Hum Mol Genet; 2017 Oct 01; 26(R2):R151-R159. PubMed ID: 28977438
    [Abstract] [Full Text] [Related]

  • 2. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A, Kononenko NL, Rigo F, Bennett CF, Wirth B.
    Am J Hum Genet; 2019 Jul 03; 105(1):221-230. PubMed ID: 31230718
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD, Duque S, Iyer CC, Zaworski P, McGovern VL, Taylor SJ, von Herrmann KM, Kobayashi DT, Chen KS, Kolb SJ, Paushkin SV, Burghes AH.
    PLoS One; 2016 Jul 03; 11(12):e0167077. PubMed ID: 27907033
    [Abstract] [Full Text] [Related]

  • 5. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C, Ramos DM, Pyles NJ, Ng SY, Gorz M, Pilato CM, Ling K, Kong L, Ward AJ, Rubin LL, Rigo F, Bennett CF, Sumner CJ.
    Neuron; 2017 Jan 04; 93(1):66-79. PubMed ID: 28017471
    [Abstract] [Full Text] [Related]

  • 6. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
    Williams JH, Schray RC, Patterson CA, Ayitey SO, Tallent MK, Lutz GJ.
    J Neurosci; 2009 Jun 17; 29(24):7633-8. PubMed ID: 19535574
    [Abstract] [Full Text] [Related]

  • 7. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM.
    Drugs Today (Barc); 2017 Jun 17; 53(6):327-337. PubMed ID: 28799578
    [Abstract] [Full Text] [Related]

  • 8. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH.
    Sci Transl Med; 2011 Mar 02; 3(72):72ra18. PubMed ID: 21368223
    [Abstract] [Full Text] [Related]

  • 9. Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.
    Dominguez CE, Cunningham D, Venkataramany AS, Chandler DS.
    Hum Genet; 2022 Feb 02; 141(2):239-256. PubMed ID: 35088120
    [Abstract] [Full Text] [Related]

  • 10. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V, Guerra M, Di Rosa V, Compagnucci C, Sette C.
    J Neurochem; 2020 Apr 02; 153(2):264-275. PubMed ID: 31811660
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN, Lee BM, DiDonato CJ, Singh RN.
    Future Med Chem; 2015 Apr 02; 7(13):1793-808. PubMed ID: 26381381
    [Abstract] [Full Text] [Related]

  • 13. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges.
    Haque US, Yokota T.
    Genes (Basel); 2024 Jul 30; 15(8):. PubMed ID: 39202360
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW, Yokota T.
    Methods Mol Biol; 2018 Jul 30; 1828():57-68. PubMed ID: 30171534
    [Abstract] [Full Text] [Related]

  • 16. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model.
    Wang J, Bai J, OuYang S, Wang H, Jin Y, Peng X, Ge X, Jiao H, Zou J, He C, Xiao P, Song F, Qu Y.
    Hum Mol Genet; 2022 May 19; 31(10):1635-1650. PubMed ID: 34888619
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS, Rose FF, Rindt H, Glascock JJ, Shababi M, Miller MR, Osman EY, Yen PF, Garcia ML, Martin BR, Wetz MJ, Mazzasette C, Feng Z, Ko CP, Lorson CL.
    Hum Mol Genet; 2013 May 01; 22(9):1843-55. PubMed ID: 23390132
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, Talbot K, UK SMA Research Consortium.
    Dis Model Mech; 2017 Aug 01; 10(8):943-954. PubMed ID: 28768735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.